SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

MLYS

Mineralys Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor for FDA feedback ahead of the December 2026 PDUFA date; any safety concerns or delays could trigger volatility. Positive momentum supports long positioning ahead of decision, but risks remain around approval and commercial uptake.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$28.43
T+0 close · Mar 9, 2026 · via day close
Latest settled
−11.85%
T+60 · $25.06
Vs SPY
−23.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $28.43entry
  2. T+1 · 8mo ago −1.62%α −1.51% · $27.97
  3. T+5 · 8mo ago −11.99%α −11.09% · $25.02
  4. T+20 · 7mo ago −2.36%α −2.20% · $27.76
  5. T+60 · 6mo ago −11.85%α −23.54% · $25.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatment for adult hypertension, and set a PDUFA action date of December 22, 2026. While the Phase 2 Explore-OSA trial missed its primary endpoint of reducing apnea-hypopnea index in sleep apnea patients, it showed clinically meaningful blood pressure reduction and a favorable safety profile, supporting the drug's potential in resistant hypertension.

Key Facts

  • FDA accepted NDA for lorundrostat with PDUFA date of December 22, 2026
  • Lorundrostat demonstrated 6.2 mmHg placebo-adjusted systolic BP reduction in Explore-OSA trial (p < 0.0003)
  • Primary endpoint (AHI reduction) in Explore-OSA trial was not met
  • Drug showed favorable safety profile with no serum potassium excursions above 5.5 mmol/L
  • NDA supported by positive Phase 3 Launch-HTN and Phase 2 Advance-HTN trials

Financial Impact

Potential blockbuster approval in 2026 for a $219B U.S. hypertension market with high unmet need

revenuevaluationmarket_cap

Risk Factors

  • FDA may require additional data or delay approval despite acceptance
  • Failure in Explore-OSA primary endpoint may raise questions about broader indications
  • Commercial success depends on differentiation from existing antihypertensives

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252329

Track record

35 reports on MLYS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
  2. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
  4. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
  6. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  7. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  8. Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
  9. Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
  10. Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
Showing 10 of 35

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026